Many Anthera Pharmaceuticals, Inc.(ANTH) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Anthera Pharmaceuticals Inc was Reiterated by Piper Jaffray on Dec 29, 2016 to Overweight, Lowers Price Target to $ 1.35 from a previous price target of $7 .Anthera Pharmaceuticals Inc was Reiterated by H.C. Wainwright on Dec 29, 2016 to Buy, Lowers Price Target to $ 3 from a previous price target of $10 .Anthera Pharmaceuticals Inc was Downgraded by Citigroup to Neutral on Dec 29, 2016. Anthera Pharmaceuticals Inc was Downgraded by Jefferies to Hold on Dec 29, 2016.
Company has reported several Insider transactions to the SEC, on Nov 18, 2015, Colin Hislop (Chief Medical Officer) sold 12,500 shares at 5.31 per share price.On Oct 13, 2015, Debra Odink (Chief Technology Officer) sold 1,205 shares at 6.15 per share price.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 4 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): The mean estimate for the short term price target for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) stands at $1.59 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $3 while the lower price target estimate is at $1.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) witnessed a decline in the market cap on Tuesday as its shares dropped 0.27% or 0.0017 points. After the session commenced at $0.64, the stock reached the higher end at $0.647 while it hit a low of $0.615. With the volume soaring to 901,006 shares, the last trade was called at $0.6362. The company has a 52-week high of $4.9. The company has a market cap of $27 million and there are 41,955,126 shares in outstanding. The 52-week low of the share price is $0.51.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Companys clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjogrens Syndrome, Graves Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.